C., & Stefanski, A., for the SURMOUNT-1 Investigators
Our study is subject to several limitations
IGF-1 LR3 is a modified analog of human Insulin-Like Growth Factor-1, engineered with two structural changes an arginine substitution and a 13-amino acid N-terminal extension that reduce its binding to IGF-1 binding proteins
Furthermore, the quality of evidence across studies varied, with some trials having a high risk of bias due to issues such as inadequate blinding, incomplete outcome data, and selective reporting
At Balanced Medical Solutions, we differentiate ourselves from others by keeping our fees the same, regardless of changes to your medication dosage